New research published in Nature medicine reveals that the willingness to obtain a COVID-19 vaccine was considerably higher in developing countries (80% of respondents) than in the United States (65%) and Russia (30%).
The study provides one of the first insights on vaccine acceptance and hesitation in a wide selection ofmiddle-income countries (LMIC), which spans more than 20,000 respondents and brings together researchers from more than 30 institutions, including the International Center for Growth (IGC), Innovations for Poverty Action (IPA), WZB Berlin Science Science Center, Yale Institute for Global Health, Yale Research Initiative on Innovation and Scale (Y-RISE) and HSE University (Moscow, Russia).
Personal protection against COVID-19 was the main reason for vaccine acceptance among LMIC respondents (91%), and concern about side effects (44%) was the most common reason for hesitation. of the vaccine. Healthcare workers were considered the most reliable sources of information on COVID-19 vaccines.
The study is at a critical juncture when vaccine shipments are slow to reach the majority of the world’s population and COVID-19 cases are on the rise in many parts of Africa, Asia and Latin America. The findings suggest that prioritizing vaccine distribution in low- and middle-income countries should produce high yields in expanding global vaccination coverage.
“As COVID-19 vaccine supplies enter developing countries, the coming months will be key for governments and international organizations to focus on designing and implementing effective vaccine recruitment programs,” said Niccoló Meriggi, country economist for IGC Sierra Leone and co-study. author. “Governments can use this evidence to develop campaigns and communications systems to ensure that those seeking a vaccine actually follow suit.”
The researchers, who conducted the surveys between June 2020 and January 2021, noted that vaccine acceptance may vary over time and with the information people have at their disposal. Although evidence on the safety and efficacy of available COVID-19 vaccines has become clearer over the past six months, serious but rare side effects may have been undermined. public confidence.
Saad Omer, director of the Yale Institute for Global Health and co-author of the study, said: “What we have seen in Europe, the United States and other countries suggests that vacant hesitation it can complicate policy decisions and therefore hinder the rapid and widespread adoption of vaccines. Governments in developing countries can begin to attract trusted people like health workers now to send messages about vaccines secondary effects that it is accurate, balanced and easily accessible to the public “.
“In all countries, we note that the acceptance of COVID-19 vaccines is generally slightly lower than that of other vaccines, perhaps because of their novelty. However, the pro-vaccine attitudes we see in income countries low and medium give us reason to be optimistic about uptake, ”said Alexandra Scacco, a senior WZB researcher and co-author of the study. “We hope the evidence from our study can help inform strategies to expand global vaccination against COVID-19.”
Shingai Machingaidze et al, Understanding hesitation against COVID-19, Nature medicine (2021). DOI: 10.1038 / s41591-021-01459-7
Provided by Innovations for Poverty Action
Citation: Study Finds Vaccination Hesitation Is Less in Poorest Countries (2021, July 16), Retrieved July 16, 2021 at https://medicalxpress.com/news/2021-07-vaccine- hesitancy-poorer-countries.html
This document is subject to copyright. Apart from any fair treatment for private study or research purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.